Back to News
Market Impact: 0.25
Halozyme, Argenx Expand ENHANZE Collaboration With Two Additional Targets
Source: Nasdaq
Healthcare & BiotechTechnology & InnovationCompany Fundamentals
Halozyme expanded its global collaboration with argenx, granting argenx exclusive access to Halozyme’s ENHANZE drug-delivery technology for two additional therapeutic targets. The article excerpt does not provide financial terms or the resulting total number of licensed targets.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
ARGX0.40
HALO0.50
More News
- Halozyme stock rises after winning injunction against Merck
- Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
- Why is SK Hynix stock gaining today?
- Elon Musk blames Indian 'oligarchs' for stalling Starlink launch
- Former world No. 1 Jon Rahm's lawyer tells court Spaniard is done with LIV Golf after three seasons
- Anthropic will be 'most ridiculous IPO' of year, analyst says
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Evaluate AI Report Writers for Financial Analysis
- Weekly Update: Sector Analysis, Improvements on Research Data, and Performance Enhancements